Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of vixarelimab in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Vixarelimab (vixarelimab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement | Phase 2 | Status: TERMINATED